

1 **Supplemental Material**

2

3 **Efficacy and Safety of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression**
4 **Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study**

5 **Journal:** *CNS Drugs*

6 **Authors:** Meredith Castro¹, Samuel T. Wilkinson², Rayan K. Al Jurdi³, Mary Pat Petrillo¹, Naim Zaki⁴,
7 Stephane Borentain⁴, Dong Jing Fu⁴, Ibrahim Turkoz⁴, Liping Sun⁵, Brianne Brown¹, Patricia Cabrera¹

8 **Affiliations:** ¹Janssen Scientific Affairs, LLC, Titusville, NJ, USA; ²Department of Psychiatry, School of
9 Medicine, Yale University, New Haven, CT, USA; ³The Menninger Department of Psychiatry and
10 Behavioral Sciences at Baylor College of Medicine, Houston, TX, USA; ⁴Janssen Research &
11 Development, LLC, Titusville, NJ, USA; ⁵Cytel, Cambridge, MA, USA

12 **Corresponding Author:**

13 Meredith Castro, PharmD, MBA, CCP

14 Janssen Scientific Affairs, LLC

15 1125 Trenton-Harbourton Road

16 Titusville, NJ, 08560


17 Email: mcastr80@its.jnj.com

18 Phone: 610-554-5503

19

20

21 **Supplemental Figure 1. Mean (A) MADRS and (B) PHQ-9 total scores (LOCF) during the**
 22 **reinduction and optimization/maintenance phases of SUSTAIN-3 among patients who previously**
 23 **experienced relapse in SUSTAIN-1 in the combined PR-ESK+AD and PR-AD+PBO groups**



24

25 *AD* antidepressant, *ESK* esketamine nasal spray, *IND* induction, *LOCF* last observation carried
 26 forward, *MADRS* Montgomery-Åsberg Depression Rating Scale, *OP/M*
 27 optimization/maintenance phase, *PHQ-9* Patient Health Questionnaire 9-item, *PR-AD+PBO*
 28 previously relapsed on an oral AD plus placebo, *PR-ESK+AD* previously relapsed on ESK plus an
 29 oral AD

30